Louisiana State Employees Retirement System Takes Position in Haemonetics Corporation $HAE

Louisiana State Employees Retirement System bought a new stake in Haemonetics Corporation (NYSE:HAE) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 13,500 shares of the medical instruments supplier’s stock, valued at approximately $761,000.

Several other hedge funds have also recently added to or reduced their stakes in HAE. Kemnay Advisory Services Inc. bought a new position in shares of Haemonetics during the 4th quarter worth approximately $26,000. True Wealth Design LLC increased its position in Haemonetics by 6,700.0% in the fourth quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 335 shares during the period. Leonteq Securities AG acquired a new position in shares of Haemonetics during the 4th quarter worth about $30,000. EverSource Wealth Advisors LLC raised its holdings in Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 396 shares during the period. Finally, Kestra Advisory Services LLC bought a new stake in Haemonetics in the 4th quarter valued at $34,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Price Performance

HAE traded up $0.84 on Tuesday, reaching $75.86. The stock had a trading volume of 8,275 shares, compared to its average volume of 875,895. Haemonetics Corporation has a fifty-two week low of $47.31 and a fifty-two week high of $87.32. The company has a current ratio of 2.95, a quick ratio of 1.87 and a debt-to-equity ratio of 1.53. The company has a market capitalization of $3.45 billion, a price-to-earnings ratio of 37.55, a price-to-earnings-growth ratio of 1.51 and a beta of 0.52. The firm has a 50-day moving average of $67.13 and a 200-day moving average of $66.41.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.01. The company had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The company’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, sell-side analysts anticipate that Haemonetics Corporation will post 5.22 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on HAE. Robert W. Baird set a $67.00 target price on Haemonetics in a report on Friday, May 8th. Barrington Research reduced their price objective on Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a research report on Tuesday, May 12th. Mizuho lifted their target price on Haemonetics from $70.00 to $85.00 and gave the company an “outperform” rating in a research report on Monday, June 15th. BTIG Research reaffirmed a “buy” rating and set a $84.00 price target on shares of Haemonetics in a research report on Friday, June 26th. Finally, JPMorgan Chase & Co. lowered their target price on Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $78.33.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.